Novel agents in renal carcinoma: a reality check

Abstract

The discovery of the molecular mechanisms underlying development of renal cell carcinoma have allowed for the development of novel targeted therapy for treatment of this disease. Recently, multiple agents have become approved by regulatory authorities for the treatment of advanced renal cell carcinoma, including sunitinib, sorafenib, bevacizumab (with interferon alpha), pazopanib, temsirolimus and everolimus. While these therapies have generated excitement and have clearly altered the treatment paradigm, multiple limitations have been elucidated over time. These include but are not limited to the fact that treatment is not associated with complete responses, a significant number of patients are primarily refractory to treatment, and clinical trials mostly include clear cell histology. Furthermore, the role of these therapies in the treatment of brain metastases remains unclear and therapies can have considerable toxicities. RECIST criteria (Response Evaluation Criteria In Solid Tumors) can be inadequate for the assessment of these modalities’ treatment efficacy, and biomarkers predictive of individual patient benefit have been elusive. This review summarizes the major clinical data and discusses these limitations.